Syrris to double sales force
High demand of Syrris' batch and flow chemistry reactors has forced them to double their sales force to cope with demand.
High demand of Syrris' batch and flow chemistry reactors has forced them to double their sales force to cope with demand.
The new 'whole' DNA microarray promises to lower the cost and increase the speed of drug discovery processes.
Lpath's anticancer therapy gains patent protection due to its novel lipid-targeting mechanism.
A round up of recent product releases from across the industry.